Roche signs biggest-ever obesity drug deal

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.Read more...

Dad of 7-year-old with rare condition 'very scared' as Ontario family can't afford $300K annual treatment

Cena Hermus, 7, was two years old when she was diagnosed with a rare, life-threatening disorder that causes severe obesity. The medication she needs costs around $300,000 annually, something family members, who now live in Hamilton, say they can't afford.

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.

Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date. The post Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity appeared first on MedCity News.

Waist-to-height ratio more accurate than BMI for detecting childhood obesity

Body mass index (BMI) was almost three times more likely to classify children as overweight than waist circumference-to-height ratio, according to a new study.

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.